BW 723C86
Latest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anxiolytics
- Mechanism of Action Serotonin 2B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 02 Dec 1999 New profile
- 02 Dec 1999 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)